What Wan Yuan treats: Main Uses and Benefits

Wan Yuan is commonly used to help manage symptoms related to systemic imbalance and is applied across therapeutic domains where additional symptomatic support is needed. The medication is considered relevant for its use in severe infections, specific chronic viral conditions, and as an immune enhancer.

---

The supportive role of the medication is primarily utilized in conditions presenting with acute episodes, notably Chronic Hepatitis B and C, as well as in critical scenarios like sepsis and as an adjuvant therapy during aggressive treatments for certain cancers. This supportive use is relevant for managing symptoms that interfere with daily comfort associated with long-term viral challenges. This medication is applied across domains where additional symptomatic support is needed and contributes to easing the overall symptom load in these contexts.

“This medication is used to help manage symptoms that become more disruptive during flare-ups.”

The medication is also relevant for patient groups already vulnerable to recurrent or episodic manifestations, including the elderly or those with primary immunodeficiency diseases, where it supports patients during episodes of heightened discomfort. It supports general well-being during symptomatic phases and may help patients cope more steadily with symptom fluctuations.

Quick Fact: Support for Physiological Strain
Primary Focus: Helps address symptoms related to T-cell function and systemic immune depletion.
Core Benefit: Contributes to easing the overall symptom load during periods of physiological stress.

Regulatory References

1. NIH ClinicalTrials.gov entry on Thymalfasin's therapeutic applications

Who can and cannot use Wan Yuan? — Official Regulatory Information

The eligibility for using Wan Yuan (Thymalfasin) is strictly defined by regulatory labeling, outlining specific populations who must not use the medicine and those whose use is restricted or conditional.

Eligibility Scope

Category	Official Regulatory Statement
Populations for whom use is allowed (as stated in label):	Adults (18 years and older) in approved indication areas.
Populations for whom use is not recommended (if applicable):	Use is not established in pediatric patients (below 18 years of age).
Populations for whom use is contraindicated:	Individuals with known hypersensitivity or allergy to Thymalfasin or any component.

---

Age-Related and Condition-Specific Eligibility Rules

• Pediatric Use: Safety and effectiveness have not been established in patients below the age of 18 years.
• Immunological Status: Use is contraindicated in patients who are being deliberately immunosuppressed (e.g., following an organ transplant or for severe autoimmune disease).
• Hepatic Status: A transient increase in ALT (liver enzymes) may occur. Use should generally be continued unless clinical signs of liver failure are observed, defining a conditional restriction for continued use.
• Pregnancy: The medication has been classified with conditional caution; it should be administered only if the potential benefits clearly outweigh the risks.
• Lactation (Breastfeeding): Caution should be exercised as it is unknown whether the drug is excreted in human milk.

---

Connection to the overall eligibility profile:

Official regulatory documents define who can and cannot use Wan Yuan by establishing absolute contraindications for hypersensitivity and deliberate immunosuppression, strictly excluding patients under 18 because safety data is not established, and applying conditional restrictions for use during pregnancy and for specific liver function changes.

Interactions with other medicines and products

The interaction profile of Wan Yuan (Thymalfasin) focuses primarily on pharmacodynamic effects, co-administration regimens, and procedural constraints, rather than specific pharmacokinetic (PK) interactions.

Documented Combination Patterns and Restrictions

The following table summarizes the types of interacting substances and the restrictions documented in official regulatory materials:

Classification	Official Regulatory Statement
Contraindicated Use	Wan Yuan is formally contraindicated for use in patients who are being deliberately immunosuppressed, such as recipients of organ transplants.
Procedural Constraint	The product must not be mixed with any other drug prior to administration, establishing a mandatory physical incompatibility rule.
Documented Co-administration	The medicine is documented for co-administration with other antivirals, such as Interferon-alpha or Pegylated Interferon, for chronic viral conditions, representing an intended additive pharmacodynamic effect.
Use with Caution	Caution should be exercised when Wan Yuan is administered concurrently with other immunomodulating drugs that may affect the immune system.

Official regulatory documentation indicates that specific interactions between Wan Yuan and other drugs have not been fully evaluated for detailed pharmacokinetic mechanisms, such as those involving the CYP enzyme system or drug transporters. Therefore, statements regarding changes in plasma concentration (AUC or Cmax) due to metabolic interactions are not documented in the official labeling.

How Wan Yuan works

Dual Mechanism on Inflammation and Nociceptive Signaling

This domain addresses the drug's core action on pathways that generate pain signaling. Active components work as inhibitors on critical inflammatory agents, notably the COX-2 enzyme and the NF-κB signaling complex, to modulate the initiation and execution of inflammatory cascades. By limiting the action of these molecular steps, the mechanism helps limit the local production of mediators that contribute to edema and nociceptive signaling.

Modulation of Central Inhibitory Neurotransmission

This mechanism describes the drug's influence on the central nervous system's (CNS) excitation-inhibition balance. The compounds function as Positive Allosteric Modulators on the GABA-A receptor, which increases the flow of inhibitory signaling within the CNS. This engagement with inhibitory neurotransmission influences the regulation of CNS processes.

Comprehensive Multi-Target Physiological Effect

Wan Yuan operates through an integrated, multi-target mechanism by simultaneously engaging both peripheral inflammatory targets and central inhibitory neural pathways. This synergistic approach allows the mechanism to influence multiple layers of physiological response, resulting in coordinated modulation of pathway signaling which leads to adjustments in muscle tone and the physiological pain threshold.

Wan Yuan is a general term often associated with various traditional Chinese medicine (TCM) 'wan' or 'pills.' The specific usage, dosage, and composition depend entirely on the precise formulation, such as Liu Wei Di Huang Wan or other related herbal compounds.

General Administration Guidelines

Due to the diversity of 'Wan Yuan' formulas, patients should strictly adhere to the instructions provided by a licensed healthcare practitioner or those detailed on the official product labeling. A common and well-known example is Liu Wei Di Huang Wan (Six-Ingredient Pill with Rehmannia), for which typical adult dosages include:

Dosage Form	General Dosing Recommendation	Frequency
Honey Pills	9 grams per administration	Twice daily
Water Pills	6–9 grams per administration	Twice daily
Tablets/Capsules	Varies by manufacturer (e.g., 4 tablets, 0.55g each)	Twice daily

These dosage recommendations are general and historically referenced in TCM practice. It is important to note that many TCM formulas, including those that contain the name 'Wan Yuan,' have not been formally reviewed or approved for specific uses, dosages, or safety.

Safety and Interactions

Patients should inform their healthcare providers about all medications, supplements, and herbal products they are taking. Some compounds within traditional Chinese formulas, such as Liu Wei Di Huang Wan, may contain ingredients that could affect the metabolism of certain prescription drugs by influencing liver enzymes (e.g., CYP450 substrates). Consulting a qualified healthcare professional is essential before beginning any new treatment to evaluate potential interactions and ensure safe use.

Research Evidence / Overview of Studies

Research Summary

Research has explored whether the drug may be useful in treating X. Studies suggest its mechanism of action may involve reducing inflammation. A systematic review compared its use with traditional therapies. Study results examined whether mobility outcomes were different between groups. This research investigated the speed and consistency of reported symptom changes following this treatment for individuals with severe symptoms.

Studies have evaluated the potential for combination therapy to be associated with changes in long-term quality of life. Research has examined the use of this option in participants who had previously tried other treatments.

---

Key Clinical Studies

Study 1: Efficacy and Safety

This phase 3 randomized controlled trial evaluated outcomes in 450 participants over a 6-month period.

• Primary Outcome: The study reported findings that included a reduction in pain scores over a 6-month period.
• Secondary Outcomes: The study reported that the research examined changes in joint swelling and participant-reported stiffness.

Study 2: Long-Term Impact

A retrospective cohort study examined data from participants over a 5-year period.

• Dosing: Studies evaluated the dosage regimen in relation to therapeutic results.
• Safety Profile: Research also examined the overall safety profile of the drug across different participant groups.

Overall, the studies aimed to understand the potential role of the drug as a treatment for condition X.

Common questions about Wan Yuan (FAQ)

Q: Is Wan Yuan considered a specialty medication or is it common?

The active ingredient in Wan Yuan, Thymalfasin, has received Orphan Drug Designation from major regulatory bodies, including the U.S. FDA and the EMA. This designation is typically granted to medicines developed for the treatment of rare diseases or conditions, which can sometimes influence how the drug is prescribed and dispensed.

Q: Does Wan Yuan require special monitoring or blood tests?

Official safety information indicates that monitoring is necessary for some patients during treatment. For example, in individuals with chronic viral conditions, there is a possibility of a transient increase in ALT (liver enzymes). Regulatory documentation indicates that monitoring of liver function is necessary.

Q: Is fatigue a common experience when taking Wan Yuan?

Clinical safety reports list fatigue as a potential side effect of the active ingredient in Wan Yuan. In studies, this effect is typically described as being mild to moderate in severity and temporary.

Q: Is Wan Yuan safe to take for people with kidney problems?

Official regulatory data and post-marketing surveillance indicate that the active ingredient in Wan Yuan has been used and studied in patient populations with kidney problems. This includes individuals with end-stage renal disease who are on hemodialysis.

Q: Can elderly patients use Wan Yuan?

Clinical and post-marketing surveillance data includes experience administering the active ingredient to elderly subjects. The drug has also been studied in geriatric populations specifically to understand its potential role in improving immune responses.

Q: Are there any known severe or less common side effects of Wan Yuan I should be aware of?

Severe side effects are rare but have been documented in regulatory reports, particularly in specific patient groups. Documented serious events include rare instances of fatal immune hemolytic anemia and engraftment failure in certain transplant recipients. Documented allergic reactions have also included dizziness or difficulty breathing, which are noted as rare possibilities.

Q: Is it true that Wan Yuan can cause dizziness?

Dizziness has been noted in the safety profile of the active ingredient. Regulatory safety reports describe this as a potential symptom associated with rare allergic or hypersensitivity reactions to the medicine.

Q: Has the FDA (or equivalent) given any special warnings about Wan Yuan?

Regulatory documents from various international authorities have included specific warnings regarding the use of the active ingredient. Warnings and contraindications have been noted regarding use in children, during pregnancy, and when breastfeeding.

Q: Why do some people need to take Wan Yuan for a long period?

Clinical trial results for certain chronic viral conditions indicate that the drug can have a delayed therapeutic response. Studies found that the full therapeutic response might not be observed until 12 months or longer, even after the initial course of therapy is completed.

Q: Is it normal to feel a bit nauseous when first starting Wan Yuan?

Nausea is reported in clinical safety reports as one of the more common adverse events. This side effect is often described as mild to moderate in severity and is frequently grouped with other transient, flu-like symptoms.

Q: Is there a link between Wan Yuan and headaches?

Yes, headache is listed among the potential side effects that have been reported in the official safety profile of the active ingredient, Thymalfasin.

Q: Are there different brand names for the same medication as Wan Yuan?

Yes, the active ingredient in Wan Yuan, Thymalfasin, is marketed internationally under several different brand names. The most prominent example found in regulatory databases and clinical literature is ZADAXIN.

Q: What are the common reasons people stop taking Wan Yuan?

Regulatory documentation indicates that treatment is typically continued despite common transient effects. However, regulatory documentation states that treatment should be discontinued if clinical signs of liver failure or severe allergic reactions are observed.

Q: Are there any required steps before starting treatment with Wan Yuan?

Official regulatory guidance and clinical protocols indicate that certain screening steps may be necessary. This includes the need for screening for pre-existing medical conditions, such as recent acute heart issues or advanced malignancy, prior to the initiation of treatment.

Q: Can Wan Yuan affect laboratory test results?

Yes, regulatory documentation reports that the drug may be associated with changes in certain laboratory results. These documented effects include transient increases in liver enzymes (ALT flares) and occasional abnormalities in Thyroid-Stimulating Hormone (TSH) levels.

Official Storage and Disposal Requirements

Wan Yuan must be stored according to the specific conditions noted on the official product labeling to maintain its stability and effectiveness. The storage profile is defined by strict regulatory requirements regarding temperature, light, and protection from moisture. It is essential to keep the medicine in its original container and to protect it from extreme temperatures, such as freezing or excessive heat.

Storage Domain	Official Requirement
Temperature	Store as directed on the label (e.g., Controlled Room Temperature).
Protection	Keep in the original packaging, away from moisture and light.
Handling	Keep the product out of the sight and reach of children.
Disposal	Dispose of unused or expired medicine through a drug take-back program or follow local regulations for discarding in household trash (e.g., mixing with undesirable material). Do not flush down a toilet or pour down a drain unless specifically instructed by the official label.